4 documents found, page 1 of 1
Alectinib-induced anemia with acanthocytosis: To proceed or discontinue treatme...
Simões, Filipa; Sequeira, Telma; Rosa, Rita; Desterro, Joana; Almodovar, Maria TeresaALK gene rearrangements are important oncogenic driver alterations in non-small-cell lung cancer and a predictive factor. When present, it enables the use of tyrosine kinase inhibitors, such as Alectinib. This drug can lead to anemia and erythrocyte morphological changes. We present the case of a 72-year-old patient diagnosed with stage IV non-small cell lung cancer treated with Alectinib in the first line. The...
New approaches in RET and MET in NSCLC
Silva, Sónia; Sequeira, Telma; Barata, FernandoThe era of precision medicine has resulted in the identification of several genomic alterations that can be targeted with novel therapies. In lung adenocarcinomas, a histology that accounts for nearly 50% of all cases of lung cancer, a few genomic targets have been linked with effective targeted therapies. For patients with advanced-stage lung adenocarcinomas, molecular testing is now a standard part of diagnos...
AT LAST! It was not a progression!
Paulinetti Camara, Raquel; Lopes, Kelly; Barbosa, Miguel; Sucena, Inês; Simão, Carla; Mota, Paulo; Matias, Dina; Sequeira, Telma; Almodovar, TeresaIntroduction: Nivolumab is approved in Portugal for non-small cell metastatic lung cancer, as one of the indications, after progressing on chemotherapy. As an immune checkpoint inhibitor (ICI) immune-related adverse events (irAE) are possible reactions. Case report: A 64-year-old man with stage III lung adenocarcinoma who progressed after chemoradiotherapy and first line metastatic chemotherapy started nivoluma...
Immunotherapy in Non-small Cell Lung Cancer: a Review
Sequeira, Telma; Almodovar, M. TeresaImmunotherapy has revolutionized the field of oncology by utilizing the body's immune system to target and eliminate cancer cells. In non-small cell lung cancer (NSCLC), immunotherapeutic agents such as immune checkpoint inhibitors (ICIs) have shown promising results. ICIs target receptors like PD-1, PD-L1, and CTLA-4 to enhance the immune response against tumors. However, resistance mechanisms to immunotherapy...